OpenAI just unveiled GPT-Rosalind, a frontier reasoning model purpose-built for biology, genomics, and drug discovery. It beats GPT-5.4 on six of 11 LABBench2 tasks and landed in the 95th percentile against human experts on RNA sequence prediction. While model access requires trusted vetting, OpenAI also dropped a free research plugin on GitHub.
Moderna just rolled out ChatGPT Enterprise across its thousands of employees, with staff building 750 custom GPTs in just two months. Use cases range from Dose ID—which analyzes clinical trial data to optimize vaccine dosages—to legal review bots. Why it matters: Moderna is betting that generative AI can allow a few thousand people to operate like a 100,000-person pharma giant, aiming to launch 15 new treatments in five years.
Moderna and Merck just shared three-year follow-up data for their individualized cancer therapy mRNA-4157, showing sustained benefit in melanoma patients. Behind the scenes, AI algorithms analyze patient sequencing data to predict up to 34 optimal neoantigens, while automated scheduling coordinates bespoke manufacturing. Phase 3 trials are now underway.
